Natera

This video reflects on the progress we’ve made, with a gracious nod to what comes next at Natera.

It brings together different perspectives, from how the outside world sees our work, to the voices of patients and families sharing what this experience looks like in their own words. It also reflects the work happening behind the scenes across teams and disciplines.

Most of us know someone impacted by cancer, planning for a baby, or navigating life after a transplant. It’s something we think about every day, and we’re honored to support people through some of life’s most important moments.

We’re proud of the progress. Grateful for the trust patients place in us. And clear on how much more there is to do.

If you have a few minutes, it’s worth a watch.

Join us for a practical, APP-led discussion on integrating Prospera™ Heart with DQS testing into transplant care.

Register here: ow.ly/P31J5104Iy7

• Explore how two different transplant centers define the role of an APP in this evolving world of post-transplant care.
• Discover the benefits of integrating Prospera into the post-transplant workflow.
• Discuss real-world cases where a non-invasive alternative to surveillance biopsy can help drive clinical decisions.

Whether you're considering using dd-cfDNA testing or looking to strengthen how it's used in your center, you'll leave with actionable insights on how to integrate Prospera into practice.

Today we announced that Solomon Moshkevich has been appointed Chief Executive Officer of Natera.

Solomon is a 15-year veteran of Natera and has been an instrumental leader driving our growth in women’s health and our rapid expansions into organ health and oncology.

We’re deeply grateful to Steve Chapman, who has served successfully as Natera’s CEO since 2019 and helped grow our company into a global leader in cell-free DNA testing and precision medicine. Steve will support a seamless transition as a consultant to the company and advisor to the board.

Congratulations, Solomon, and thank you, Steve, for the years of excellent leadership and dedication to Natera.

You can read more in this press release: ow.ly/uRqO5104j0H

@SMoshkevich

Head and neck cancer can recur in up to 60% of patients, making early detection of recurrence critical.

Signatera™ was recently featured in three new peer-reviewed publications in npj Precision Oncology, JAMA Otolaryngology, and Advances in Radiation Oncology. Collectively, the studies demonstrate Signatera’s ability to detect recurrence in advance of imaging and help predict which patients may benefit from adjuvant chemotherapy.

These datasets build on the prospective Phase 2 SINERGY trial, which was selected for an oral plenary at the 2026 Multidisciplinary Head and Neck Cancers Symposium earlier this year. We’re proud to continue contributing important research that we hope will help patients with this type of cancer.

Read more about these publications in our press release: ow.ly/Pb2n5103PYr

Medicare coverage for Signatera™ just expanded to the most common type of liver cancer.

Signatera has met coverage requirements from the CMS MolDX program in hepatocellular carcinoma (HCC). The coverage includes serial testing in the surveillance setting for patients with early-stage HCC who have no post-surgical evidence of disease.

We’re pleased to share this news as clinical evidence continues to grow.

Read the full press release:
ow.ly/EgmJ5103lnO